摘要
目的 对照观察冠心病慢性心力衰竭治疗中不同剂量阿托伐他汀治疗效果,为临床药物治疗剂量选择提供科学参考.方法 取2015年6月~2017年4月就诊浙江省德清县中医院采用20 mg/d阿托伐他汀药物治疗方案治疗冠心病慢性心力衰竭的54例患者为研究对照组,另取同期就诊应用40 mg/d阿托伐他汀药物治疗方案治疗的54例冠心病慢性心力衰竭患者作为研究观察组.将LDL-C、LVESD、LVEDD、LVEF、hs-CRP、6MWT、NT-proBNP等指标作为疗效评价依据,通过观察2组治疗前后上述指标水平评价临床疗效,观察治疗后不良事件在2组的发生情况.结果 临床疗效各项评价指标水平治疗前组间比较差异无统计学意义(P<0.05).前述临床疗效评价指标在治疗后均有不同程度改善,观察组改善效果优于对照组(P<0.05).结论 每天口服40 mg阿托伐他汀药物治疗方案是冠心病慢性心力衰竭患者阿托伐汀应用剂量最佳选择,该剂量范围内阿托伐汀治疗有效性与安全性有保障,显著改善患者临床症状,促进生活质量改善,值得临床应用推广.
Abstract
Objective To observe the effect of different doses of atorvastatin in the treatment of chronic heart failure of coronary heart disease (CHD), and to provide scientific reference for the choice of clinical medication. Methods 54 cases from June 2015 ~2017 year in April in our hospital with 20mg/d atorvastatin therapy regimen in the treatment of chronic heart failure of coronary heart disease patients as the study group, 54 cases of chronic heart failure of coronary heart disease patients with another force selected by 40mg/d atorvastatin therapy regimen as study group. LDL-C, LVESD, LVEDD, LVEF, hs-CRP, 6MWT, NT-proBNP and other indicators as evaluation basis, through the observation of the two groups before and after treatment the indexes to evaluate clinical efficacy, adverse events were observed after treatment in two groups. Results There was no significant difference between the groups before and after treatment, and there was no statistical significance(P<0.05). The indexes of clinical curative effect were improved in different degree after treatment, and the improvement effect in observation group was better than that in control group (P<0.05). Conclusion Atorvastatin 40mg daily oral drug treatment of chronic heart failure in patients with coronary heart disease is the best choice of atorvastatin dose, the dose range of atorvastatin treatment effectiveness and safety protection, improve clinical symptoms, promote the improvement of the quality of life, worthy of clinical application.
NETL
NSTL
维普
万方数据